体外膜氧合治疗重度急性呼吸窘迫综合征
这项国际临床试验将极重度ARDS患者随机分配至立即静脉-静脉ECMO组或继续传统治疗组(对照组难治性低氧血症时可交叉至ECMO)。极重度ARDS定义为满足以下三条标准之一:PaO2:FIO2低于50 mmHg超过3小时;PaO2:FIO2低于80 mmHg超过6小时;或动脉血pH低于7.25且PaCO2至少60 mmHg超过6小时。主要终点60天死亡率在ECMO组为35%(44/124),对照组为46%(57/125),差异未达统计学显著(RR 0.76,95%CI 0.55-1.04,P=0.09)。ECMO组输血相关出血事件(46% vs 28%)和严重血小板减少(27% vs 16%)更多,缺血性卒中更少(0% vs 5%)。
要点
- 极重度ARDS患者立即ECMO较传统机械通气(含ECMO补救)未显著降低60天死亡率(35% vs 46%,RR 0.76,95%CI 0.55-1.04,P=0.09)。
- 对照组28%(35/125)患者交叉至ECMO,交叉距随机化平均6.5±9.7天,其中57%(20/35)死亡。
- ECMO组输血相关出血事件多于对照组(46% vs 28%,绝对风险差18个百分点,95%CI 6-30)。
- ECMO组严重血小板减少多于对照组(27% vs 16%,绝对风险差11个百分点,95%CI 0-21)。
- ECMO组缺血性卒中少于对照组(0% vs 5%,绝对风险差-5个百分点,95%CI -10至-2)。
适用人群与场景
- 极重度ARDS患者,满足以下三条标准之一:PaO2:FIO2低于50 mmHg超过3小时;PaO2:FIO2低于80 mmHg超过6小时;或动脉血pH低于7.25且PaCO2至少60 mmHg超过6小时。
诊断标准与关键阈值
- 极重度ARDS纳入标准(三条满足其一):PaO2:FIO2低于50 mmHg持续超过3小时;PaO2:FIO2低于80 mmHg持续超过6小时;动脉血pH低于7.25伴PaCO2至少60 mmHg持续超过6小时。
处置流程与药物剂量
- ECMO组:立即行静脉-静脉ECMO。
- 对照组:继续传统治疗;难治性低氧血症时可交叉至ECMO。
研究设计与关键结果
- 国际临床试验,随机分配极重度ARDS患者至立即静脉-静脉ECMO组(n=124)或继续传统治疗组(n=125);主要终点为60天死亡率。
- 60天死亡:ECMO组44/124(35%)vs 对照组57/125(46%),RR 0.76(95%CI 0.55-1.04),P=0.09。
- 对照组35例(28%)交叉至ECMO,交叉距随机化平均6.5±9.7天,其中20例(57%)死亡。
- 并发症总体无显著差异;ECMO组输血相关出血事件46% vs 对照组28%(绝对风险差18个百分点,95%CI 6-30),严重血小板减少27% vs 16%(绝对风险差11个百分点,95%CI 0-21),缺血性卒中0% vs 5%(绝对风险差-5个百分点,95%CI -10至-2)。
证据类型、等级与局限
- 证据类型:国际随机对照临床试验(EOLIA,NCT01470703)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在极重度ARDS患者中,立即静脉-静脉ECMO较传统机械通气(含ECMO补救)未显著降低60天死亡率;ECMO组输血相关出血和严重血小板减少更多,缺血性卒中更少。
指南或共识出处
- EOLIA试验,ClinicalTrials.gov编号NCT01470703,由Direction de la Recherche Clinique et du Développement和法国卫生部资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy of venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome (ARDS) remains controversial.
METHODS: In an international clinical trial, we randomly assigned patients with very severe ARDS, as indicated by one of three criteria - a ratio of partial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 50 mm Hg for more than 3 hours; a Pao2:Fio2 of less than 80 mm Hg for more than 6 hours; or an arterial blood pH of less than 7.25 with a partial pressure of arterial carbon dioxide of at least 60 mm Hg for more than 6 hours - to receive immediate venovenous ECMO (ECMO group) or continued conventional treatment (control group). Crossover to ECMO was possible for patients in the control group who had refractory hypoxemia. The primary end point was mortality at 60 days.
RESULTS: At 60 days, 44 of 124 patients (35%) in the ECMO group and 57 of 125 (46%) in the control group had died (relative risk, 0.76; 95% confidence interval [CI], 0.55 to 1.04; P=0.09). Crossover to ECMO occurred a mean (±SD) of 6.5±9.7 days after randomization in 35 patients (28%) in the control group, with 20 of these patients (57%) dying. The frequency of complications did not differ significantly between groups, except that there were more bleeding events leading to transfusion in the ECMO group than in the control group (in 46% vs. 28% of patients; absolute risk difference, 18 percentage points; 95% CI, 6 to 30) as well as more cases of severe thrombocytopenia (in 27% vs. 16%; absolute risk difference, 11 percentage points; 95% CI, 0 to 21) and fewer cases of ischemic stroke (in no patients vs. 5%; absolute risk difference, -5 percentage points; 95% CI, -10 to -2).
CONCLUSIONS: Among patients with very severe ARDS, 60-day mortality was not significantly lower with ECMO than with a strategy of conventional mechanical ventilation that included ECMO as rescue therapy. (Funded by the Direction de la Recherche Clinique et du Développement and the French Ministry of Health; EOLIA ClinicalTrials.gov number, NCT01470703 .).
参考来源
- Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018. PMID: 29791822. doi:10.1056/NEJMoa1800385
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。